JNJ
173.89
+0.19%↑
ABBV
198.28
+0.11%↑
AZN
74.06
+0.64%↑
NVS
118.5
+1.46%↑
ABT
131.52
-2.16%↓
JNJ
173.89
+0.19%↑
ABBV
198.28
+0.11%↑
AZN
74.06
+0.64%↑
NVS
118.5
+1.46%↑
ABT
131.52
-2.16%↓
JNJ
173.89
+0.19%↑
ABBV
198.28
+0.11%↑
AZN
74.06
+0.64%↑
NVS
118.5
+1.46%↑
ABT
131.52
-2.16%↓
JNJ
173.89
+0.19%↑
ABBV
198.28
+0.11%↑
AZN
74.06
+0.64%↑
NVS
118.5
+1.46%↑
ABT
131.52
-2.16%↓
JNJ
173.89
+0.19%↑
ABBV
198.28
+0.11%↑
AZN
74.06
+0.64%↑
NVS
118.5
+1.46%↑
ABT
131.52
-2.16%↓
24h
Praegune
Min
8.18
Max
8.77
Sissetulek | -13M 4.6M |
---|---|
Müük | 126M 2.7M |
Kasumimarginaal | 169.368 |
Töötajad | 225 |
EBITDA | 77M -14M |
Soovitused | Osta |
---|---|
12 kuu keskmine prognoos | +192.77% upside |
Turukapital | 28M |
---|---|
Eelmine avamishind | 10.75 |
Eelmine sulgemishind | 8.28 |
By Acuity
100%
0%
364 / 374 Pingereas Healthcare
By Trading Central
Kindlus
Bearish Evidence
0.306 / 0.33939 Toetus ja vastupanu
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
20. veebr 2025, 11:34 UTC
FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN
DJ
Loe
20. veebr 2025, 11:34 UTC
FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN
DJ
Loe
20. veebr 2025, 11:33 UTC
FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN
DJ
Loe
20. veebr 2025, 11:33 UTC
FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN
DJ
Loe
20. veebr 2025, 11:31 UTC
FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN
DJ
Loe
20. veebr 2025, 11:30 UTC
FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M
DJ
Loe
Hinnamuutus
By TipRanks
12 kuu keskmine prognoos
Keskmine 25.5 USD 192.77%
Kõrge 43 USD
Madal 8 USD
Põhineb 3 Wall Streeti analüütiku instrumendi FibroGen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
By TipRanks
Osta
3 ratings
1
Osta
2
Hoia
0
Müü
Põhineb 3 analüütiku instrumendi FibroGen Inc aktsia reitingul - viimase 3 kuu andmed.
By Trading Central
Lühikene perspektiiv
Bearish Evidence
Recent bearish events outweigh bullish events.
Keskpikk perspektiiv
Weak Bearish Evidence
Bearish events outweigh bullish events.
Pikk perspektiiv
Weak Bearish Evidence
There is one bearish event.
By Acuity
Uudiste sentiment
Väga tugevad languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$